Tech Company Financing Transactions
Vigil Neuroscience Funding Round
Vida Ventures, Atlas Venture and Cormorant Asset Management participated in a $90 million Series B funding round for Vigil Neuroscience. The round was announced on 8/19/2021.
Transaction Overview
Company Name
Announced On
8/19/2021
Transaction Type
Venture Equity
Amount
$90,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
300 Technology Sq. 8th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
We are discovering and developing novel therapeutics that take advantage of breakthroughs in basic science and human genetics of microglia. Vigil's drug pipeline consists of therapeutic candidates targeting critical microglial signaling pathways in which loss-of-function mutations cause life-threatening neurodegenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ivana Magovcevic-Liebisch
Chief Financial Officer
Jennifer Ziolkowski
Chief Medical Officer
Spyros Papapetropoulos
Chief Scientific Officer
Richard Fisher
Controller
Pam Meneses
Vice President
Jessica Stromme
VP - Bus. Development
Evan Thackaberry
VP - Operations
Andrew Marsh
VP - Operations
Weeteck Yeo
VP - Regulatory Affairs
Samantha Zappia
Browse more venture capital transactions:
Prev: 8/19/2021: Osaro venture capital transaction
Next: 8/19/2021: Rapid Robotics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs